BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28438385)

  • 1. Small molecules inhibit STAT3 activation, autophagy, and cancer cell anchorage-independent growth.
    Zhou D; Springer MZ; Xu D; Liu D; Hudmon A; Macleod KF; Meroueh SO
    Bioorg Med Chem; 2017 Jun; 25(12):2995-3005. PubMed ID: 28438385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
    Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
    Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines.
    Kim HS; Kim T; Ko H; Lee J; Kim YS; Suh YG
    Bioorg Med Chem; 2017 Oct; 25(19):5032-5040. PubMed ID: 28705432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.
    Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK
    Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.
    Liu CY; Su JC; Huang TT; Chu PY; Huang CT; Wang WL; Lee CH; Lau KY; Tsai WC; Yang HP; Shiau CW; Tseng LM; Chen KF
    Mol Oncol; 2017 Mar; 11(3):266-279. PubMed ID: 28084011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small Molecular Leads Differentially Active Against HER2 Positive and Triple Negative Breast Cancer Cell Lines.
    Badran A; Atia-Tul-Wahab ; Fayyaz S; Baydoun E; Choudhary MI
    Med Chem; 2019; 15(7):738-742. PubMed ID: 30398120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel small molecules targeting the USP21/JAK2/STAT3 axis for the treatment of triple-negative breast cancer.
    Long L; Xu J; Qi X; Pen Y; Wang C; Jiang W; Peng X; Hu Z; Yi W; Xie L; Lei X; Wang Z; Zhuo L
    Eur J Med Chem; 2024 Jul; 273():116500. PubMed ID: 38776807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a novel small-molecule inhibitor of Fam20C that induces apoptosis and inhibits migration in triple negative breast cancer.
    Zhao R; Fu L; Yuan Z; Liu Y; Zhang K; Chen Y; Wang L; Sun D; Chen L; Liu B; Zhang L
    Eur J Med Chem; 2021 Jan; 210():113088. PubMed ID: 33316691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum complexes inhibit HER-2 enriched and triple-negative breast cancer cells metabolism to suppress growth, stemness and migration by targeting PKM/LDHA and CCND1/BCL2/ATG3 signaling pathways.
    Bai X; Ali A; Lv Z; Wang N; Zhao X; Hao H; Zhang Y; Rahman FU
    Eur J Med Chem; 2021 Nov; 224():113689. PubMed ID: 34293698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-Guided Design of a Small-Molecule Activator of Sirtuin-3 that Modulates Autophagy in Triple Negative Breast Cancer.
    Zhang J; Zou L; Shi D; Liu J; Zhang J; Zhao R; Wang G; Zhang L; Ouyang L; Liu B
    J Med Chem; 2021 Oct; 64(19):14192-14216. PubMed ID: 34605238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy.
    Feng T; Cao W; Shen W; Zhang L; Gu X; Guo Y; Tsai HI; Liu X; Li J; Zhang J; Li S; Wu F; Liu Y
    Oncotarget; 2017 Jan; 8(1):329-344. PubMed ID: 27861147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.
    Wu X; Zahari MS; Renuse S; Kelkar DS; Barbhuiya MA; Rojas PL; Stearns V; Gabrielson E; Malla P; Sukumar S; Mahajan NP; Pandey A
    Oncotarget; 2017 Jan; 8(2):2971-2983. PubMed ID: 27902967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells.
    Cai J; Xia J; Zou J; Wang Q; Ma Q; Sun R; Liao H; Xu L; Wang D; Guo X
    FEBS Open Bio; 2020 Apr; 10(4):535-545. PubMed ID: 32027103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer.
    Kandil SB; Jones SR; Smith S; Hiscox SE; Westwell AD
    Molecules; 2020 Jul; 25(15):. PubMed ID: 32751931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer.
    Zhao YQ; Yin YQ; Liu J; Wang GH; Huang J; Zhu LJ; Wang JH
    Acta Pharmacol Sin; 2016 Sep; 37(9):1237-50. PubMed ID: 27397540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
    Qin JJ; Yan L; Zhang J; Zhang WD
    J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymoquinone Inhibits Proliferation and Migration of MDA-MB-231 Triple Negative Breast Cancer Cells by Suppressing Autophagy, Beclin-1 and LC3.
    Ünal TD; Hamurcu Z; Delibaşı N; Çınar V; Güler A; Gökçe S; Nurdinov N; Ozpolat B
    Anticancer Agents Med Chem; 2021; 21(3):355-364. PubMed ID: 32767958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
    Wu B; Fathi S; Mortley S; Mohiuddin M; Jang YC; Oyelere AK
    Bioorg Med Chem; 2020 Mar; 28(6):115345. PubMed ID: 32061484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
    Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
    J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.